600222 太龍藥業
按盤價 
5.480 +0.040 (+0.735%) | 2024/09 - 九個月 人民幣(K¥) | 與去年同期 比較 | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | 2020/12 人民幣(K¥) | ||
| 營業總收入 | 1,340,673 | -7.08% | 2,069,909 | 1,960,694 | 1,604,517 | 1,417,097 | |
| 減：營業總成本 | 1,346,043 | -8.68% | 2,035,858 | 1,994,618 | 1,536,757 | 1,392,331 | |
| 其中:營業成本 | 985,571 | -8.57% | 1,505,186 | 1,488,614 | 1,141,450 | 1,042,225 | |
| 財務費用 | 44,162 | 11.76% | 53,533 | 63,552 | 84,027 | 67,653 | |
| 資產減值損失 | 4,532 | -194.74% | (2,462) | (17,314) | (22,024) | (6,895) | |
| 公允價值變動收益 | 6,121 | 932.39% | (534) | (8,177) | (10,171) | 2,383 | |
| 投資收益 | 1,051 | -126.39% | (5,890) | (2,912) | 3,655 | 4,664 | |
| 其中：對聯營企業和合營企業的投資收益 | (970) | -77.31% | (8,327) | (6,069) | 34 | 1,144 | |
| 營業利潤 | 24,672 | -218.96% | 44,167 | (70,779) | 35,608 | 32,989 | |
| 利潤總額 | 24,421 | -216.35% | 42,962 | (82,849) | 7,450 | 29,240 | |
| 減：所得稅費用 | (5,527) | 276.11% | (1,867) | (7,086) | 671 | 1,644 | |
| 淨利潤 | 29,948 | -253.41% | 44,829 | (75,763) | 6,779 | 27,596 | |
| 減：非控股權益 | 1,052 | -140.54% | 1,273 | (3,559) | 783 | (1,645) | |
| 股東淨利潤 | 28,896 | -270.72% | 43,557 | (72,204) | 5,995 | 29,241 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.052 | -273.00% | 0.077 | -0.128 | 0.011 | 0.054 | |
| 每股派息 (元) * | 0.028 | -- | -- | -- | 0.010 | 0.016 | |
| 每股淨資產 (元) * | 2.736 | 8.23% | 2.751 | 2.737 | 2.893 | 2.533 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 08/11/2024 16:29 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
